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The Issue
Menopause isanaturalprocess thatoccurs inallwomenwholive long
enough.Manywomenexperiencenomenopausal symptomsoronly
mild ones that do not require active medical management. How-
ever, a substantial proportion of women (about 20%) experience
bothersomesymptoms,suchashotflushes,nightsweats,andtrouble
sleeping.1TheNational InstituteofHealthandCareExcellence(NICE),
based in the United Kingdom, has recently published guidelines for
diagnosis and management of menopause. These guidelines pro-
vide clear and evidence-based advice to support both primary care
physicians and those specializing in the care of women inmidlife.
Objective
ThisGuidelinewaspublishedbyNICE inNovember 20152 to inform
health careprofessionals and their patients and to standardize care.
It includes recommendationsondiagnosis ofmenopauseandon in-
dividualized care of symptomatic women. Several versions of the
guidelines are available: a “patient-friendly” version for women; a
“short” summary of the recommendations with tables of the ben-
efits and risksofhormonetherapy (HT); and the “full” version,which
containsdetails of the literature searches, quality assessmentof the
evidence, results ofmeta-analysis, and how the recommendations
were derived from the evidence (https://www.nice.org.uk).
The Evidence
All review questions posed (17 in all) were subject to systematic re-
viewing of the current evidence base, andmeta-analysis when ap-
propriate. The evidence was assessed using the GRADE system
(Grading of Recommendations, Assessment, Development and
Evaluations Working Group).3 Recommendations were written by
aguidelinedevelopmentgroupcomprisinggynecologists,otherphy-
sicians, nurses, laymembers, anda technical team including review-
ers, statisticians, and health economists.
We discuss selection of the recommendations from the NICE
Guideline2 to illustrate thebreadthof topics covered. Thenumbers
included are those used in the Guideline itself for easy cross-
referencing. Some are included in the Box, but all should be re-
viewed in the context of the complete Guideline document.
Diagnosis
Moderate- to very-low-quality evidence from studies of the diag-
nostic accuracyof biochemical tests forwomenolder than45years
concluded thatmeasurementof follicle-stimulatinghormone (FSH)
added no useful information to the clinical diagnosis of the meno-
pause and therefore should not be used. In symptomatic women,
thediagnosis ofmenopause shouldbebasedonage andmenstrual
cyclicity only (recommendation4).However,measurement of FSH
Box. Selected Recommendations From The National Institute
of Health and Care Excellence for the Diagnosis and Treatment
ofMenopausea
Recommendation 7: Give information tomenopausal women that
includes:
• Common symptoms and diagnosis
• Benefits and risks of treatments for menopausal symptoms
• Long-term health implications of menopause
Recommendation 14: Offer women hormone therapy (HT) for
vasomotor symptoms after discussing with them the short-term
(up to 5 years) and longer-term benefits and risks. Offer a choice of
preparations as follows:
• Estrogen and progestogen to womenwith a uterus
• Estrogen alone to womenwithout a uterus
Recommendation 25: Offer menopausal womenwith, or a high
risk of, breast cancer:
• Information that the selective serotonin reuptake inhibitors
paroxetine and fluoxetine should not be offered to womenwith
breast cancer who are taking tamoxifen
• Referral to a health care professionalwith expertise inmenopause
Recommendation 42: Ensure that menopausal women and health
care professionals involved in their care understand that HT:
• Does not increase cardiovascular disease risk when started in
women younger than 60 years
• Does not affect the risk of dying from cardiovascular disease
Recommendation 49: Explain to women around the age of natural
menopause that:
• Thebaseline risk of breast cancer forwomenaroundmenopausal
agevaries fromonewoman to another according to thepresence
of underlying risk factors
• HT with estrogen alone is associated with little or no change in
the risk of breast cancer
• HT with estrogen and progestogen can be associated with an
increase in the risk of breast cancer
• Any increase in the risk of breast cancer is related to treatment
duration and reduces after stopping HT.
Recommendation 56: Diagnose premature ovarian insufficiency in
women younger than 40 years based on:
• Elevated follicle-stimulating hormone levels in 2 blood samples
taken 4 to 6 weeks apart
Recommendation 61: Explain to womenwith premature ovarian
insufficiency:
• The importance of starting treatment eitherwithHTor a
combinedhormonal contraceptive and continuing treatment until
at least the age of naturalmenopause (unless contraindicated)
a The Guideline2 contains 63 recommendations relating to clinical care and
7 research recommendations; some subsections of recommendations are
included here, numbered as in the Guideline.
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is of value in younger women with symptoms where diagnosis is
uncertain (recommendation 56).
Treatment
Althoughamajorityofmenopausalwomenrequire littleornomedi-
cal intervention for symptoms, somewill require treatment, and all
must be given information (recommendation 7) aboutmenopause
and what to expect. In the absence of randomized clinical trials in-
volving a direct comparison of all treatments of interest, a network
meta-analysis was undertaken to estimate the relative effective-
ness of treatments for vasomotor symptoms, which informed the
cost-effectiveness analysis. The network meta-analysis concluded
that HT was the most effective treatment for common meno-
pausal symptoms such as hot flushes (recommendation 14). Com-
parisonwasmadebetweenprescribedmedications suchasHTand
selective serotonin reuptake inhibitors or serotonin-norepineph-
rine reuptake inhibitors (SSRIs/SNRIs), nonprescribed prepara-
tions suchasphytoestrogensorherbalpreparations, andsomenon-
pharmacological therapies such as cognitive behavior therapy,
acupuncture, andhypnosis. Both thebenefits and the risksof treat-
ments were reviewed. For HT, longer-term outcomes such as car-
diovascular disease (recommendation 42), breast cancer (recom-
mendation 49), and osteoporosis preventionwere considered and
tables of risk estimates, including any change in risk that could be
attributed to HT, compiled. The balance of benefits and harms var-
ies among women according to their personal risk factors for car-
diovasculardiseaseandbreast cancer.Butoverall,moderate to low-
quality evidence suggests that there is no increase in cardiovascular
disease riskwithHT (recommendation 42)when such treatment is
started in women younger than 60 years. However, evaluation of
general health and the delivery of appropriate advice is important.
In a given patient, risk factors for disorders such as cardiovascular
disease (eg, diabetes and high blood pressure or lipid levels)might
be present, and these could affect the treatment offered (recom-
mendation43). Such risk factorsmustbeadequately controlledbe-
fore commencinghormone therapy. Theguidelines suggest that all
women should have access to a sympathetic, knowledgeable
practitioner to discuss their needs.
For those for whom HT is not appropriate (eg, women with
breast cancer), theGuidelinegroup reviewedmoderate-quality evi-
dence relating toalternative treatments (recommendation25), par-
ticularlySSRIs/SNRIs.However,warningsare includedregardinguse
of SSRIs in those being treated with tamoxifen and also the use of
St John’s Wort, which showed limited benefit.
Although the number of women experiencingmenopause be-
fore age40years is small (1%), theoccurrencehas significant impli-
cations for long-termhealth, bothphysical andpsychological, sodi-
agnosis andmanagement is extremely important.4 Evidence in this
areawas low to very-lowquality, since the studieswere often small
andatseriousriskofbias.However, implementingrecommendations
todiagnosebasedonmenopausal symptomsandelevatedFSH lev-
els,asopposedtoanti-Mullerianhormonetesting,shouldcutthetime
todiagnosis (recommendations56and58) andensure thatwomen
receive relief of any symptoms and long-termhealth advice to pro-
tectparticularly thecardiovascularandskeletal systems(recommen-
dation61). Theevidence comparingHTand the combinedoral con-
traceptive inthemanagementofprematureovarian insufficiencywas
low tovery-lowquality, and the final choice of treatmentwill follow
discussion between thewoman and her health care professional.
Implementation
Further resources are available fromNICE thatmayhelp to support
Guideline implementation, including the development of audit-
able quality standards and working with professional organiza-
tions to maximize educational opportunities for trainees and
continuous professional development of more senior staff.
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